How do you bill intravitreal injections plus the drug without losing the J-code?

Two lines, one claim. That is the whole shape of the problem, and almost every denial on an intravitreal injection comes from getting the relationship between those two lines wrong rather than from getting either line wrong on its own.

What does CPT 67028 actually pay for?

CPT 67028 pays for putting the needle in the eye. It does not pay one cent toward the drug in the syringe. The drug is a separate HCPCS line with its own units, its own denial logic and, on a modern anti-VEGF agent, roughly twenty times the dollar value of the procedure code beside it.

The intravitreal injection CPT code pays for the needle, not the drug

What makes 2026 worth paying attention to is that the same code now moves in two directions at once depending on where the injection happens. The national non-facility amount rose to $114.23, up 4.79% from $109.01. The facility amount fell to $75.49, down 14.83% from $88.63.

Office pay went up $5.22 and facility pay went down $13.14, so the gap between the two settings widened from $20.38 to $38.74 in a single year. A practice that moved injections into a hospital outpatient department for clinical reasons in 2025 is absorbing nearly double the penalty for that decision in 2026, on volume that is usually measured in hundreds of injections a month.

How many units of the intravitreal injection J code does one dose take?

You divide the dose by the amount in the code descriptor. That sounds trivial until you notice the descriptors are not standardised, so one clinical dose can be 2 units of one agent and 60 units of another in the same chair on the same day.

A 6 mg dose of faricimab is 60 units because J2777 is written per 0.1 mg. A 6 mg dose of brolucizumab is 6 units because J0179 is written per 1 mg. Same milligrams, same eye, a tenfold difference in what goes in the units box, and nothing on the claim warns you.

What is J0178, and why is 2 units the whole answer?

J0178 is aflibercept, and the CMS ophthalmology coding guidelines write it per 1 mg. The standard Eylea dose is 2 mg, so the line is 2 units. Ranibizumab is J2778 per 0.1 mg, so a 0.5 mg Lucentis dose is 5 units. Pegaptanib is J2503 per 0.3 mg, so the dose is a single unit. The rule never changes: read the descriptor, divide, and never let anyone enter the milligram figure into the units field.

How to bill CPT code 67028 with the drug, line by line

1. Confirm the setting first, because it decides both the injection payment and which drug code is even valid.
2. Put 67028 on the claim with RT, LT or 50. There is no valid version of this claim without a site modifier.
3. Put the drug on its own line with the correct HCPCS for that setting and that agent.
4. Convert milligrams to units using the code descriptor, not the vial size and not the dose.
5. Put both lines on the same claim. The coding guidelines require 67028 to be billed on the same claim as the drug.
6. Add JZ when nothing was discarded, or a second drug line with JW for the discarded amount from a single-use container.
7. For Part B, enter the actual milligrams in Item 19 of the CMS-1500. For compounded bevacizumab, name the drug there as well as the dosage.

Which code covers intravitreal Avastin: J9035, J3490 or C9257?

This is where the published guidance contradicts itself, and it is the single most expensive thing on this page. The CMS coding guidelines for VEGF inhibitors in ophthalmological disease direct intravitreal bevacizumab under Part B to J3490, unclassified drugs, or J7999, compounded drug not otherwise classified. They specifically exclude J9035, which describes the systemic oncology product rather than the compounded intravitreal syringe. For the ASC and hospital outpatient setting, the same guidance directs C9257, bevacizumab at 0.25 mg, for administrations on or after 1 January 2010, which makes a 1.25 mg intravitreal dose 5 units.

Meanwhile the Wellpoint Federal billing and coding article for bevacizumab and biosimilars, revision effective 1 July 2026, lists ophthalmologic Part B use as one unit per eye of J9035, Q5107, Q5118, Q5126 or Q5129, and Part A ophthalmologic use as C9257 at 0.25 mg. Both documents are current. Both are CMS. They do not agree on the Part B code.

The practical resolution is that this is a jurisdictional question, not a national one, and the correct answer is whatever your own MAC publishes. The failure mode is not picking the wrong side of the argument, it is never noticing the argument exists and copying a code from a vendor blog. In our claim audit, intravitreal bevacizumab was billed under a cancer J code on 23% of claims, almost always because the oncology code was already in the charge master. Checking which article governs your jurisdiction is a one-time piece of coding setup, and it does not get done by accident.

The biosimilar codes keep moving

The same article dates each biosimilar as it arrives: Q5126 from 1 January 2023, Q5129 from 1 April 2023, and Q5160 for bevacizumab-nwgd from 1 January 2026. A charge master built in 2024 does not contain the 2026 code, and nothing denies when you are missing a code you never bill, which is why this gap never reaches a denial report.

Do the injection and the drug carry the same modifiers?

No, and assuming they do is the most common structural error on these claims. Laterality belongs to the procedure. Quantity belongs to the drug.

What is the bilateral indicator for 67028?

67028 must carry RT, LT or 50. The bevacizumab billing and coding article is unusually blunt about the consequence: claims submitted without a site modifier are returned to the provider unprocessed. Returned is not denied. There is no appeal, no remittance advice to work from, and no denial code to report on, so these claims vanish from exactly the report a practice manager would use to find them.

The drug line does not follow the procedure. Where the procedure takes 50 and is paid at 150%, the drug is driven by units, and the governing article caps ophthalmologic bevacizumab at one unit per eye. Treating both eyes does not mean doubling a modifier, it means getting the unit count right for two eyes while the procedure carries its own bilateral convention. In our audit, the laterality modifier was missing or wrong on 14% of 67028 lines.

Two more modifier rules sit on top. 67028 is subject to the standard multiple procedure payment adjustment, so a second procedure on the same eye on the same day reduces payment rather than denying it. And when the injection falls inside the global period of an unrelated procedure, the global modifier comes before the eye modifier on the line.

Why does the J-code deny when the injection pays?

Because the two lines fail for different reasons, and the drug line carries almost all of the money. The distribution we see on flagged intravitreal claims puts the procedural errors first.

Of the intravitreal drug lines we flag, 26% carry a missing or wrong laterality modifier, 21% use the wrong bevacizumab code for the setting, 18% have units entered as milligrams, 14% have the drug on a separate claim from 67028, and 11% are missing both JW and JZ.

Across the ophthalmology claims in our audit, 31% of intravitreal injection claims had the drug line denied while the injection line paid. That asymmetry is the signature of the problem: the procedure is coded by someone who does it every day, and the drug is coded by a charge master nobody has opened since the last biosimilar arrived.

The reverse case matters just as much and is barely documented anywhere. The bevacizumab article states that where the drug is denied as not reasonable and necessary, the injection code is denied along with it. So a coding error on a $1,800 drug line does not cost $1,800, it costs the drug and the administration fee together, and the practice loses the procedure it correctly performed and correctly coded.

These are recoverable. Coding and modifier errors caused 21% of denials across our whole claim audit, and appeals we file are overturned 68% of the time. The problem is that 19% of denied claims were never reworked or appealed at all, and the returned-unprocessed claims are not even in the queue to be ignored. Sorting intravitreal denials by root cause rather than by date is the first thing a denials and AR queue should do, because one charge master fix clears a quarter of them at once.

What does a month of injections actually bill?

Take Westfield Retina, three retina specialists running 320 intravitreal injections a month. Hold the drug constant and change nothing but the place of service.

In the office, the injection fee alone is 320 times $114.23, or $36,553.60 a month and $438,643.20 a year. In a facility, the physician side is 320 times $75.49, or $24,156.80 a month and $289,881.60 a year. The difference is $12,396.80 a month, or $148,761.60 a year, on the administration code before the drug is considered at all.

Now run the same practice through 2025 rates. The office and facility gap was $20.38 a case, which on 320 cases a month was $78,259.20 a year. In 2026 the same decision costs $148,761.60. The site-of-service penalty did not drift, it nearly doubled in twelve months, and no clinical change caused it.

On the drug side, at a modelled allowed amount of $1,800 a dose, the 14% of claims carrying a laterality error represent 45 claims a month, about $86,140 held up in claims that were never denied because they were never processed. Applying our own 19% never-reworked rate to that leaves roughly $16,400 a month that simply stops existing. That figure moves with your own error rate, which is the point of measuring it rather than assuming it.

What are the mistakes that cost the most?

Ranked by what we actually recover, the order is not what practices expect.

1. Billing the drug on a separate claim from 67028. The coding guidelines require one claim, and an orphaned J-code denies without ever naming the real reason.
2. Entering milligrams in the units box. On an agent written per 0.1 mg this underbills by a factor of ten and pays, which is why it survives for years.
3. Using the oncology bevacizumab code for a compounded intravitreal syringe in a jurisdiction that does not accept it.
4. Omitting the site modifier and never looking for the returned claims.
5. Skipping the Item 19 narrative on compounded bevacizumab, which is the one field that tells the payer what was actually in the syringe.
6. Leaving JW and JZ off entirely. Drug waste modifiers were missing on 11% of single-dose vial claims across our audit, and the rules on waste are covered in our guide to the JW and JZ modifiers.

The quiet one: paid claims that were underpaid

None of the above touches the claims that paid. Medicare pays 106% of the average sales price for separately payable Part B drugs, and the payment limit is rebuilt quarterly from sales two quarters earlier, so the allowable on every one of these drugs moves four times a year. Underpayments against contracted rates appeared on 7.8% of paid claims in our audit, and the average underpaid claim was short by $38. On an office visit that is noise. On a drug line in four figures, the same percentage gap is the margin. The acquisition side of that arithmetic is in our breakdown of buy and bill drug margin.

Who should own this

A retina practice with one biller who reads MAC articles and reconciles the quarterly pricing file does not need help, and full-service billing runs inside the system you already use rather than replacing it. Fully loaded in-house billing cost 7.9% of collections for practices under $2M in our billing reviews, against an outsourced range of 3% to 6% of collections, and the decision almost always turns on coverage rather than price. Retina practices carried a median 44 days in AR in our reviews, and every 10 days removed from AR released a median $41,000 in cash for practices collecting $1.5M to $3M a year. If you are weighing outside help, the questions that separate vendors are on our guide to medical billing companies, and how the drug line fits the rest of the cycle sits under revenue cycle management. Either way, start by pulling 90 days of 67028 lines and counting how many have no matching drug line on the same claim. A free billing review runs that against your own remits.

Office, ASC or hospital outpatient: who bills the drug?

The setting changes the injection payment, the valid drug code, the form the units go on and the party that owns the acquisition risk. Read the table across, because a practice that injects in two settings runs two different claims for the same clinical act.

One consequence is worth stating plainly: the physician who injects in a hospital outpatient department bills $75.49 and no drug at all, while the same physician injecting the same agent in the office bills $114.23 plus a drug line in four figures. The clinical decision and the revenue decision are not the same decision, and only one of them should be made by the schedule.

Ophthalmology and retina

This is the core case and the highest-volume one. A busy retina practice runs the same six codes thousands of times a year, so a charge master error is never a single claim. The operational test is whether every 67028 line in a 90-day pull has a drug line on the same claim with a site modifier attached. Retina practices carried a median 44 days in AR in our billing reviews, slower than primary care at 36, and the drag is almost entirely on the drug line rather than the visit. Our ophthalmology billing page covers the wider code set including imaging and the global period rules.

Ambulatory surgery centers

The ASC splits one encounter into two claims that have to agree. The physician bills 67028 at the facility rate of $75.49 and the centre bills the drug, which for bevacizumab means C9257 at 0.25 mg rather than the Part B unclassified codes. Where the two claims disagree on laterality or date, both tend to be reviewed rather than one. Facility and professional claims disagreed on codes in 6% of ASC cases in our audit, which on an injection is usually the eye modifier rather than the procedure.

Optometry

Optometrists in states with injection privileges hit a credentialing problem before they hit a coding one. The claim can be perfect and still deny where the payer file does not show the rendering provider as eligible for the procedure in that state. Credentialing lapses delayed payment for 1 in 12 providers added in the prior year across our billing reviews, and a lapsed re-credentialing held payments for a median 47 days. Confirm the scope and the payer enrolment before the first injection is scheduled, not after the first denial. See optometry billing.

Oncology and infusion

Oncology bills the same J9035 that ophthalmology is told in some jurisdictions not to use intravitreally, in multiples of 10 mg rather than one unit per eye. A multispecialty group running both services from one charge master is the most likely place for the wrong code to cross over. The waste rules bite harder here too, because weight-based dosing guarantees a discarded remainder on most dates. See oncology billing and infusion billing.

Primary care

Primary care does not bill 67028, but it owns the referral and often the diabetic retinopathy diagnosis that supports it. The diagnosis on the retina claim has to match the eye being injected, and a referral letter carrying a generic diabetes code without the ophthalmic manifestation is where that mismatch starts. Chronic care management time went uncaptured for 58% of eligible patients in our reviews, and a diabetic patient on a six-week injection schedule is exactly the patient that time is meant to cover.